London--(Marketwire - December 13, 2007) -

              Curidium Medica plc ("Curidium" or the "Company")


London, UK, 13 December 2007, Curidium Medica plc, (LSE: CUR) the personalized medicine company focused on bringing the right drug to the right patient, announced that it will be presenting tomorrow Friday 14 December 2007 at the 3rd UK Biotechnology Company Showcase, in London, UK.

Dr. Anne Bruinvels, Founder & Chief Scientific Officer will be presenting Curidium's recent developments including the strategic partnership Curidium entered with Takeda Research Investment, Inc. (TRI), the corporate investment arm of Takeda Pharmaceutical Company, Limited. She will also focus on the company's progress and discuss the increasing importance of personalized medicine and targeting a drug treatment to a specific sub-population.

The presentation, entitled "Central Nervous System", is scheduled at 12.10 hours local time on 14th December October 2007 at the BERR Conference Centre, Westminster, London UK.


For further information, please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397

Chairman, Curidium Medica plc

Anne T. Bruinvels, PhD, +44 (0) 20 7554 8790

Founder & Chief Scientific Officer, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793

Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400

Blue Oar Securities Plc

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113

Financial Dynamics

Notes to Editors

Curidium Medica

Curidium is a personalized medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDxTM, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDxTM may have the potential to improve the treatment of patients with schizophrenia/ bipolar disorder.

Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

1.  Diagnostics for better identification and treatment within heterogeneous
    disease populations.

2.  Improved therapies identified through novel drug targets.

3.  Personalized medicines using companion diagnostics and targeted treatments.

Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas. Further information on Curidium can be found at the Company's website:

Curidium Medica plc (c) 2002-2007. All rights reserved.

Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.


Tel.: +44 (0)20 7554 8790,

Fax: +44 (0)20 7554 8791

                      This information is provided by RNS
            The company news service from the London Stock Exchange